Abstract Statins have been shown to possess properties that go beyond their lipid-lowering effects. These agents act on the mevalonate pathway and inhibit synthesis of cholesterol, geranylgeranyl pyrophosphate, and farnesyl pyrophosphate, which are necessary for posttranslational modification of the Rho, Rac, and Ras superfamily of proteins. Early phase studies have demonstrated that this modulation of cellular signaling can ultimately exert pro-apoptotic, anti-angiogenic, and immunomodulatory effects, and might even restore chemosensitivity in several hematologic cancers. Nonetheless, these promising preclinical results have not yet migrated from the bench to the bedside as their effectiveness as adjuvant agents in hematologic malignancies is currently uncertain. In the present review, we summarize the existing evidence stemming from preclinical and clinical studies pertaining to the use of statins as adjuvant therapies in hematologic malignancies, and discuss the new insights gained from the ongoing translational research.
Introduction
Statins have inhibitory effects on the enzyme hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase that has important cholesterol-lowering properties [1, 2] . This class of drugs inhibits the rate-limiting step in cholesterol hepatic biosynthesis, thereby decreasing the plasma LDL-cholesterol level along with mild elevation in high-density lipoprotein cholesterol and reduction in triglyceride levels [1, 3] . Statins are key components in the treatment and prevention of cardiovascular diseases, and possess properties that go far beyond their lipid-lowering effects. They are known to improve endothelial functions, participate in plaque stabilization, immunomodulation, antioxidant activity, and also act as antiinflammatory agents [4, 5] .
Statins have recently received increased attention due to their potential antineoplastic effects that are thought to be independent of the lipid-reducing properties. A multitude of experimental studies have established their pro-apoptotic, anti-proliferative, anti-invasive, and radiosensitizing effects. Although several cellular pathways activated by statins have been identified, the precise mechanisms by which statins inhibit cancer cell growth remain elusive and likely vary with the type of malignancy. Extensive efforts are underway to establish their utility in cancer prevention and their potential use in the treatment of certain malignancies, in combination with other agents.
These drugs are generally well-tolerated, with mild gastrointestinal symptoms being the most common adverse effects. Major concerns in clinical practice are hepatotoxicity and myopathy that occur in less than 10 % of patients. Exceedingly rare, myopathy can progress to rhabdomyolysis, myoglobinuria, and acute renal failure [1, 2] . The aforementioned side-effect profile makes statins promising adjuvant drugs in the anticancer armamentarium.
In the present review, we summarize the existing evidence stemming from the preclinical and clinical studies concerning statin use in hematologic malignancies, and discuss the new findings of the ongoing translational research.
Pharmacology of statins
Statins consist of two main components: the pharmacophore that inhibits the HMG-CoA reductase enzyme in a competitive, dose-dependent, and reversible manner; and the chemically modified ring systems that are complexes of hydrophobic structure linked covalently to the pharmacophore [6] . Each ring structure is unique and represents the "fingerprint" of any given statin, defining the majority of its pharmacological properties as detailed in Table 1 [6] [7] [8] . Among the statins available on the market, simvastatin, atorvastatin, fluvastatin, and lovastatin are lipophilic, whereas pravastatin and rosuvastatin are rather hydrophilic. The lipophilic profile confers low systemic bioavailability due to an efficient first-pass liver uptake, which represents a pharmacological advantage as the liver is the primary site of cholesterol biosynthesis. Moreover, statins are chiefly metabolized by the cytochrome P450 enzymatic complex. This bears relevance as there are many agents commonly used in clinical practice that may interact with P450 enzymes, thus affecting the metabolism of HMGCoA reductase inhibitors [6] [7] [8] .
Epidemiological evidence
Over the past 20 years, none of the randomized controlled clinical trials (RCTs) of statins in cardiovascular diseases with accumulated follow-up data showed a reduction in the risk of solid tumors [9] [10] [11] [12] [13] . Of note, safety of this class of agents was confirmed by several meta-analyses [14, 15] . Notwithstanding, several epidemiological studies have suggested that HMG-CoA reductase inhibitors may, in fact, prevent certain solid malignancies such as melanoma, breast, colon, and prostate cancers [16] [17] [18] [19] [20] . Likewise, it has been suggested that chronic statin use is linked with a trend toward a lower cancerrelated mortality rate [21] .
A number of case-control studies have been reported in the literature demonstrating inconsistent results on the statins use and decreased risk of hematologic malignancies [22] [23] [24] [25] CYP3A4 hepatic CYP3A4 microsomal enzyme, CYP2C9 hepatic CYP2C9 microsomal enzyme 1.29) , abating the initial excitement about a preventive effect of statins in hematologic malignancies [26] .
Intracellular effects of statins
HMG-CoA reductase, which is inhibited by the statins, represents the rate-limiting enzyme in the mevalonate pathway (Fig. 1) . Besides the biosynthesis of cholesterol, mevalonate is involved in the synthesis of isoprenoid intermediates such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). These intermediates will ultimately lead to the synthesis of geranylgeranylated proteins such as dolichol and ubiquinone that are involved in essential cellular functions such as glycoprotein synthesis, respiration, cell signaling, differentiation, proliferation, and migration [3, 21, 27, 28] . In both normal and malignant cells, statins have been shown to modulate this important pathway by depleting intracellular mevalonic acid and diminishing the metabolites FPP and GGPP, necessary for posttranslational modification of the Rho, Rac, and Ras superfamily proteins [18, 29] . Ras represents a small farnesylated GTPase that functions as a molecular switch in the transduction of a variety of signals generated by the activation of several cell surface receptors [30] . In order to acquire full biologic activity, Ras proteins undergo posttranslational farnesylation, a reaction catalyzed by farnesyltransferase. Ultimately, Ras proteins play a critical role in signal transduction, cell proliferation, and malignant transformation [18, 31] . In this regard, statins may be effective in modulating cellular signaling and differentiation by inhibiting this early step in the mevalonate pathway necessary for Ras synthesis.
Inhibition of tumor growth
In 1994, Newman et al. demonstrated that simvastatin selectively inhibits the in vitro proliferation of myeloblasts in a dose-dependent manner [32] . Subsequently, Vitols et al.
showed that simvastatin and lovastatin inhibit the cell growth in chronic lymphocytic leukemia (CLL), hairy cell leukemia, and immunoblastic B-cell lymphoma [33] . These antiproliferative effects were hypothesized to be mediated by a negative impact on the intracellular cholesterol metabolism induced by statins. Additional studies have supported the hypothesis that the metabolites of the mevalonate pathway are essential for cell proliferation and tumor growth in a wide spectrum of neoplastic cell lines [34] [35] [36] [37] . Preclinical research studies over the last two decades suggested that statins may inhibit cell proliferation by preventing the transition from G1 to S phase in the cell cycle [3] . This cell cycle arrest is thought to be independent of the p53 pathway, Fig. 1 The mevalonate pathway being mediated by a downregulation of cyclin dependent kinases (CKD) 2 that facilitate the cell cycle progression with an associated upregulation of CDK inhibitors p21Cip1 and/or p27Kip1 [38] [39] [40] [41] [42] [43] . This inhibitory effect induced by the statins can be overcome by addition of GGPP, FPP, or mevalonate [44] . Altogether, these findings indicate that various downstream products of the mevalonate pathway play an essential role in cell cycle progression, whereas the inhibitory effects observed in statin-treated cells are indeed mediated by HMGCoA reductase inhibition.
Induction of apoptosis
HMG-CoA reductase inhibitors have been found to induce apoptosis in a variety of hematologic malignancies including acute myeloid leukemia (AML) [45] [46] [47] [48] [49] , acute lymphoblastic leukemia (ALL) [50, 51] , CLL [52] , chronic myeloid leukemia (CML) [53] , multiple myeloma [54, 55] , and adult T-cell leukemia (ATL) [56] . The proposed mechanisms of statinmediated apoptosis in AML cells are via depletion of mevalonate and, subsequently, geranylgeranylated proteins, but not farnesyl pyrophosphate or other products such as lanosterol and cholesterol [57] [58] [59] [60] [61] . Additional mechanisms may include upregulation of pro-apoptotic proteins expression such as Bax and Bim [62] , activation of proteases involved in programmed cell death such as caspases [49, 52] , cleavage of poly (ADP-ribose) polymerase (PARP) [47] , and downregulation of anti-apoptotic proteins such as Bcl-2 [21, 63, 64] . Furthermore, Young et al. proposed that increases in reactive oxygen species, nitric oxide, and intracellular calcium concentration might also be responsible for the simvastatininduced apoptosis in CML cells [53] .
Inhibition of angiogenesis
Angiogenesis is a critical process for cancer expansion, invasion, and dissemination, representing a fine balancing act between the activities of pro-and anti-angiogenic factors [65] . It has been well-documented that HMG-CoA reductase inhibitors exhibit a protective effect on endothelial function, atherosclerotic plaque stabilization, and promotion of neovascularization in ischemic tissues [66] [67] [68] . These proangiogenic properties of statins might be detrimental in patients with cancer as enhancement of vascularization would support cancer growth and progression. Nevertheless, Weis et al. showed that the process of angiogenesis can be modulated by statins in a dose-dependent manner [69] . Although lower dose statins may enhance angiogenesis via stimulation of protein kinase B and subsequent activation of endothelial nitric oxide synthase [70, 71] , higher doses (2.5 mg/kg per day) of atorvastatin and cerivastatin decrease tumor growth and vascularization both in vitro and in vivo studies [69] . Furthermore, this angiostatic effect of statins at higher doses was found to be unrelated to cholesterol reduction but primarily dependent on the absence of mevalonate and geranylated proteins.
In addition, compelling data on interaction between statins and vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) makes them promising therapeutic agents for angiogenesis inhibition. Zhao et al. demonstrated a novel mechanism in which lovastatin inhibits both ligand-induced VEGFR-2 activation through inhibition of receptor internalization and VEGF activation of PI3K/AKT pathway in endothelial cells [72] . Since angiogenesis has a central role in clinically aggressive hematologic malignancies such as nonHodgkin lymphomas [73] [74] [75] , angioimmunoblastic T-cell lymphoma [76, 77] , ALL [78] , AML [79] , and multiple myeloma [80] , inhibition of the VEGF-mediated intracellular signal via bevacizumab could be further facilitated by blocking the mevalonate pathway.
Synergism with anti-tumor therapies
Accumulating evidence demonstrates pleiotropic effects of statins on cancers, suggesting a potential use of these drugs in several hematologic malignancies. Although the precise mechanisms by which statins inhibit tumor growth remain under investigation, there is already enough pre-clinical data supporting their direct anti-leukemic effect. Furthermore, the relative safety of these compounds makes them promising candidates for adjuvant treatment, in combination with chemotherapy agents and/or targeted therapies. Herein, we analyze the current evidence of synergistic interaction between statins and different chemo-and immunotherapies in the treatment of lymphoproliferative disorders.
Nucleoside analogs
The synergetic interaction between statins and the nucleoside analog cytosine arabinoside (Ara-C) was first described by Holstein and Hohl who studied a human erythroleukemia cell line and the ara-C resistant ARAC8D cell line [81] . In order to document cytotoxicity, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed. Isobologram analysis of the combination of lovastatin and ara-C showed a combination index (CI) of 0.753 and 0.757 at 48 and 72 h, respectively, confirming the synergistic interaction as the CIs were less than 1.0. They found that this interaction does not occur at the level of RAS, but may rather involve the statins' effect of downregulating MAPK activity and preventing Ara-C induced MAPK activation [82] . Similarly, Lishner et al. found that simvastatin significantly reduced the proliferation of AML blasts. Pre-incubation of these cells with increasing concentrations of simvastatin before exposure to Ara-C enhanced the cytotoxic effect of this agent in an additive fashion, with a marked decrease in the rate of DNA synthesis [48] .
Synergistic effects between statins and purine analogs were also demonstrated by Moreau et al. in a study of Waldenstrom macroglobulinemia BCWM.1 cells using MTT assay. They found that the cytotoxicity of fludarabine was increased from 25 to 56 % using simvastatin at the concentration of 2.5 mmol/ l (CI=0.85) and further to 74 % with a concentration 5 mmol/l (CI=0.84), indicating at least an additive effect [82] . Similarly, Podhorecka et al. showed that simvastatin acted synergistically with fludarabine and cladribine inducing apoptosis in leukemic cells isolated from peripheral blood and bone marrow of CLL patients. The co-treatment simvastatinfludarabine had a CI <1.0 in 12 out of 15 samples, while simvastatin-cladribine had CI <1.0 in all except one of analyzed cases, indicating the synergic effect of these combinations. They also found that this pro-apoptotic effect was tumor-specific and spared normal lymphocytes. In addition, the rate of apoptosis caused by simvastatin alone and in combination with nucleoside analogs was independent of the markers of aggressive clinical behavior such as higher ZAP-70 and CD38 expression or advanced clinical stage according to Rai classification. Use of a nucleoside analog in combination with a statin may allow its dose reduction in order to prevent the dose-related toxicity without interfering with its effectiveness [83] .
Doxorubicin
Doxorubicin is an anthracycline that induces formation of covalent topoisomerase-DNA complexes, leading to a cell cycle arrest in the G2 phase and apoptosis, whereas statins prevent the cell transition from G1 to S phase. Thus, the combination of these drugs could, at least in theory, have an addictive therapeutic effect. In fact, several preclinical studies have shown that statins enhance the anti-tumor activity of doxorubicin in several solid tumors such as melanoma [84] , colon adenocarcinoma [85] , lung cancer [86] , and ovarian cancer [87] . Besides increasing the doxorubicin antineoplastic effect, lovastatin treatment was also associated with a lower risk for doxorubicin-associated cardiotoxicity [86, 88] .
A few studies demonstrated similar results with the use of statins in hematologic disorders. Ahn et al. examined the effect of different statins in human myeloid leukemia cells and found that simvastatin potentiated the rate of apoptosis induced by doxorubicin, paclitaxel, and 5-fluorouracil. Interestingly, no synergism was found between these agents and atorvastatin. These results suggest that statins may behave differently from one another, and specific reasons for such disparity in their effects need to be clarified in future studies [89] . In a study using rat B-cell lymphoma cells, Rozados et al. demonstrated that low doses of lovastatin as a single agent decreased tumor cell viability in vitro. Notably, use of lovastatin in combination with doxorubicin induced a significant increase in cytotoxicity when compared to the effect of each agent given alone [90] .
Pre-clinical studies have shown that statins induce apoptosis in a dose-and time-dependent manner. The optimal dosing regimen of statins when combined with other chemotherapies including anthracyclines was examined in a phase I dose escalation study [91] . Patients with relapsed multiple myeloma and non-Hodgkin lymphoma (NHL), who had been treated with at least two lines of chemotherapy, including anthracyclines, were treated with a dose-escalating regimen of simvastatin for 7 days followed by vincristine, adriamycin, and dexamethasone (VAD) in myeloma patients and cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in NHL patients. High-dose simvastatin was administered with acceptable toxicity at a dose of 15 mg/kg for 7 days followed by standard chemotherapy [91] . The results of ongoing phase II trials on the use of statins in patients with refractory NHL and myeloma are awaited (Table 2) .
Paclitaxel
Paclitaxel binds to and stabilizes microtubules, interfering with spindle formation and ultimately blocking mitosis at the metaphase-anaphase transition. In pre-clinical studies, its synergism with lovastatin was examined in human erythroleukemia (K562) and promyelocytic leukemia (HL-60) cell lines using MTT assay [92] . These malignant cells were incubated with increasing concentrations of lovastatin and/or paclitaxel for 72 h. Whereas either lovastatin or paclitaxel alone showed cytotoxic effects in a concentration dependent manner, they displayed an even greater activity in combination, with isobologram analysis showing a CI of 0.24. In an elegant experiment using flow cytometry cell cycle analysis, it was demonstrated that the combination of the two drugs resulted in a greater G2-M phase arrest than that caused by either agent alone, and co-incubation with mevalonate prevented the supra-additive effect of lovastatin and paclitaxel. In addition, lovastatin was found to enhance paclitaxel-induced apoptosis [92] . Thus, these results show that the combination of lovastatin and paclitaxel inhibited cancer cell proliferation in pre-clinical studies.
Lenalidomide and thalidomide
The effects of the simvastatin-lenalidomide combination were analyzed in myeloma cell lines by van der Spek et al. They demonstrated that simvastatin as a single agent reduced cell viability in myeloma cell lines in a time-and dose-dependent manner [93] . The calculated combination index at 4 days ranged from 0.38 to 0.86, confirming the synergistic reduction of myeloma cell viability. Furthermore, they found that this effect was due to induction of apoptosis and inhibition of proliferation. This combination enhanced the induction of caspase-8 cleavage and the downregulation of the signal transducer and activator of transcription (STAT)-3. Similar to the previous studies exploring cytotoxicity mediated by statins, they also noted that the addition of mevalonate reversed the synergism between lenalidomide and simvastatin [93] . The effects of lovastatin in combination with thalidomide were also assessed in a malignant plasma cell line in vitro. The rate of apoptosis was analyzed via Annexin V binding assay and flow cytometry, showing that co-exposure of drugs led to a higher rate of apoptosis in comparison to the one of each drug alone [94] . These data provide a rationale for the clinical evaluation of lenalidomide or thalidomide in combination with statins in patients with multiple myeloma.
Rituximab
Preclinical studies showed that statins inhibit the binding of rituximab to the CD20 antigen, resulting in a reduced antilymphoma activity of this monoclonal antibody and posing a legitimate question whether concurrent use of these drugs might adversely impact outcomes [95] . Nevertheless, a recent cohort study involving patients with diffuse large B cell lymphoma (DLBCL) treated with CHOP and rituximab (R-CHOP) and concurrent statin use showed a 5-year event-free survival (EFS) of 67.3 % in patients without statin use compared with 79 % of patients receiving statins during R-CHOP (hazard ratio [HR], 0.47; 95 % CI, 0.15-1.54). The overall survival (OS) at 5 years was 81.4 % for patients without statin use compared with 93.3 % in the statin group (HR, 0.58; 95 % CI, 0.07-4.55), thus dismissing any detrimental impact of concurrent statin use during R-CHOP treatment in terms of EFS and OS [96] . Another large prospective cohort study of newly diagnosed patients with DLBCL and follicular lymphoma (FL) found that concomitant use of a statin in rituximabtreated patients had no impact on the overall response rate and survival. Moreover, that study showed a statistically significant improvement in the EFS among FL patients when compared to patients not treated with this lipid-lowering agent (HR, 0.45; 95 % CI, 0.26 to 0.77) [97] . The observational design of the aforementioned studies should be taken into consideration as the presence of unmeasured confounding factors could have impacted their results.
A plausible explanation of the discrepancy between the in vitro and clinical results would be that the degree of inhibition of rituximab binding to CD20 antigen by statins observed in vitro may not be clinically significant, being either incomplete or transient. Furthermore, the negative effect of statins on rituximab binding might be counteracted by the potential anti-tumor effect of statins via inhibition of protein prenylation.
Imatinib
Treatment of CML with the BCR-ABL1 tyrosine kinase inhibitor (TKI) imatinib mesylate is highly effective in reducing disease progression and prolonging overall survival. However, at least a quarter of patients who initially responded to imatinib will eventually become refractory to this drug [98, 99] . Several strategies have been deployed to overcome resistance to imatinib such as its use in combination with other drugs or development of novel TKIs. In this regard, preclinical studies with CD34+ subpopulation of CML-K562 cells, which harbor greater ability of imatinib resistance, found that the combination of imatinib and simvastatin induced cell death in the CD34+ cells. The hypothesized mechanism for this synergistic interaction was thought to be dependent on the increased reactive oxygen species (ROS) as the ROS scavenger N-acetyl-L-cysteine (NAC) blocked their synergistic function [100] . Addictive effect of simvastatin in imatinib-resistant CML cell lines was recently examined by Oh et al. [101] . Studying K562, KCL22, and LAMA84 cell lines in K562-xenografted mice models, the investigators confirmed the synergistic killing effect when both drugs were co-administered, as the calculated combination indexes were 0.48, 0.64, and 0.93, respectively. Moreover, they showed that cell killing was via induction of apoptosis as well as cell cycle arrest through inhibition of tyrosine phosphorylation and activated STAT3 and STAT5 independent of BCR-ABL effects. Simvastatin suppressed the growth of K562-transplanted tumors, and co-treatment with imatinib was more effective at reducing tumor growth. Additionally, simvastatin cytotoxicity was enhanced in imatinib-resistant as opposed imatinib-sensitive CML cells [101] . Their findings support simvastatinimatinib as a potential combination therapy for imatinib resistant CML patients.
Tipifarnib
Tipifarnib is a highly selective inhibitor of farnesyltransferase (FTase) that was initially designed to prevent Ras farnesylation and its subsequent membrane localization, which is necessary for Ras-mediated signaling [102] . Although, the pre-clinical effectiveness of tipifarnib as a single agent in AML and myelodysplastic syndrome (MDS) was promising, a recent open-label phase III trial on tipifarnib in AML and MDS showed rather disappointing results [103, 104] . Harousseau et al. evaluated the efficacy of tipifarnib compared with best supportive care (BSC), including hydroxyurea, as first-line therapy in elderly patients with newly diagnosed AML [105] . A total of 457 patients were enrolled, with 24 % of the patients being 80 years of age or older. The median OS was 107 days in the tipifarnib arm and 109 days in the BSC arm. The hazard ratio (tipifarnib vs BSC) for OS was 1.02 (p=0.843). The complete response rate for tipifarnib was lower in this study (8 %) compared to previous phase II studies [105] . An alternative prenylation by a geranylgeranyl transferase has been postulated as an escape mechanism by which Ras evades the effect of tipifarnib [106, 107] . As statins are capable of blocking both geranylgeranylation and farnesylation, it could be speculated that the combined use of tipifarnib and statins might have a stronger anti-leukemia effect. In this regard, Van der Weide et al. investigated the effect of tipifarnib combined with simvastatin and in CD34+ AML cells [108] . A potentiated suppressive effect on cell survival was observed with simvastatin combined with tipifarnib when compared with either compound alone, which was characterized by an inhibition of cell cycle progression and enhanced apoptosis [108] .
Although not yet tested in the clinical setting, these results suggest that co-treatment with tipifarnib and statins may be more effective than single-agent tipifarnib in a subset of AML patients.
Statins as adjuvant antineoplastic agents: what is the current evidence?
Despite promising data of several pre-clinical studies on statin use as adjuvant treatment of hematologic malignancies, the clinical trials completed to date showed conflicting results. A recent trial of patients with relapsed or refractory multiple myeloma was conducted to investigate whether lovastatin was beneficial when co-administered with thalidomide and dexamethasone prior to autologous stem cell transplantation as a salvage therapy [109] . A total of 91 patients with refractory disease were treated with either thalidomide, dexamethasone and lovastatin (TDL group), or thalidomide and dexamethasone (TD group). Clinical response was observed in 32 % of patients in the TD group and in 44 % of TDL group. The median OS was longer in patients treated with TDL regimen than with TD regimen (47.5 versus 36.5 months, p=0.073). In addition, the progression-free survival (PFS) was significantly longer in the TDL group as compared to the patients treated with TD (28.5 versus 6 months, p= 0.0484). These results suggest that the addition of lovastatin to thalidomide and dexamethasone might improve outcomes in patients with relapsed or refractory myeloma [109] . Conversely, a phase II study found no evidence of beneficial effect of high-dose simvastatin (15 mg/kg/day) on biochemical markers and disease activity in multiple myeloma patients [110] . Similarly, simvastatin at its maximum tolerated dose (MTD) [15 mg/kg, given orally, twice daily] failed to reverse clinical resistance to VAD regimen in myeloma patients [111] . Although very effective in vitro, high-dose statins did not show convincing results when used to treat myeloma patients. An explanation for this lack of consistency in the aforementioned studies might be attributed to methodological differences including the chemotherapy regimen and the type of statin employed.
More promising results using statins were reported by Kornblau et al. in the setting of AML [112] . In this phase I trial, 15 newly diagnosed and 22 patients with relapsed AML with unfavorable or intermediate prognosis cytogenetics were treated with pravastatin, idarubicin, and high dose AraC (Ida-HIDAC) and compared to historical experience with Ida-HDAC. The toxicity profile was unchanged by the addition of pravastatin. Complete response was obtained in 11 of 15 newly diagnosed patients, including eight of ten with unfavorable cytogenetics, and 9 of 22 patients with relapsed disease. The MTD for pravastatin was not reached, despite reaching very high doses of the drug [112] . The significant proportion of patients achieving remission was encouraging and further trials evaluation the effect of statins in AML were initiated (Table 2) .
Clinical trials of statins in hematologic malignancies
There are currently several clinical trials underway that aim at testing efficacy of statins as adjuvants to conventional chemotherapy as well as in combination with newer targeted agents in several hematologic malignancies (Table 2) . Their results will be of great interest for a variety of reasons. Firstly, it is not known what individual statins are more effective in cancer therapy. Although both hydrophilic (pravastatin and rosuvastatin) and lipophilic (simvastatin and atorvastatin) statins demonstrate anti-tumor effects in pre-clinical studies, hydrophilic statins tend to be less effective at the intracellular level. Furthermore, optimal statin regimens and doses have yet to be established. Statins appear to be cytostatic at lower concentrations and cytotoxic at higher concentrations. Higher concentrations of statins required to achieve apoptosis in most studies were generally not compatible with life in animal models, which has been one of the major obstacles in their therapeutic applications as anticancer agents. The hurdles of achieving high intracellular concentrations of statins were recently demonstrated in a pilot trial of CLL patients [8] . When patients with recurrent or refractory CLL were treated with simvastatin at its MTD (7.5 mg/kg, twice daily), only low micro-molar concentration was achieved in plasma and peripheral blood mononuclear cells, which is far lower than the concentrations required for an anti-leukemia effect in vitro. In addition, it will be of great interest to clarify whether combinations of lower dose statins with certain chemotherapy agents might extend the anticancer benefits based on the level of synergism between both agents. Lastly, future studies need to determine which hematologic malignancies are most susceptible to statins. Similar to most agents with antineoplastic activity, HMG-CoA reductase inhibitors demonstrate robust efficacy in some but not all tumor types, emphasizing the importance of matching the optimal statin agent with the most susceptible hematologic malignancy.
Conclusions
There is growing evidence from preclinical studies that statins might be useful in the treatment of hematologic malignancies. Several research groups have focused their efforts in determining the spectrum of antineoplastic effects of statins in different tumor types. However, the molecular mechanisms underlying anti-tumor activity of HMG-CoA reductase inhibitors have not been fully elucidated. Accumulation of this knowledge is important in order to create a rational milieu for the utilization of these agents in the management of cancer. More importantly, although several experimental studies have demonstrated promising results, future large clinical trials should confirm whether statins are to find a role in the treatment of hematologic malignancies.
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